广泛耐药结核治疗中利奈唑胺减少不良事件的剂量策略建议
基于Nix-TB试验(N=109)数据,建立药代动力学与毒性动力学模型,模拟每日利奈唑胺1200mg与600mg方案的安全性差异。模拟显示1200mg组严重神经病变和严重贫血比例更高,而严重血小板减少无差异;治疗4周血红蛋白下降>10%可预测严重贫血,据此减量可预防60%严重贫血。
要点
- 每日1200mg利奈唑胺的严重神经病变和严重贫血比例高于600mg。
- 治疗4周血红蛋白下降>10%对预测严重贫血敏感性82%、特异性84%。
- 依据该标志物将剂量从1200mg降至600mg可预防60%严重贫血。
核心结论
- 简单的神经病变症状和血红蛋白监测可指导利奈唑胺剂量调整以避免毒性,但需前瞻性验证获益风险比。
研究设计与样本
- 基于Nix-TB试验(NCT02333799,N=109)数据的药代动力学与毒性动力学模型模拟研究。
主要发现
- 模拟显示每日1200mg与600mg利奈唑胺相比,严重神经病变中位发生率19%(90%CI 17%-22%) vs 5%(4%-7%)。
- 严重贫血中位发生率15%(90%CI 12%-17%) vs 1%(0%-2%),严重血小板减少两组均<1%。
- 神经病变一般在治疗3至6个月后发生,经方案规定管理后在发病15个月内逆转。
- 治疗4周血红蛋白下降>10%预测严重贫血的敏感性82%、特异性84%。
- 依据该标志物将剂量从1200mg降至600mg可预防60%(90%CI 45%-72%)的严重贫血。
关键数值与推荐
- 严重神经病变基于Brief Peripheral Neuropathy Screen症状评分。
- 严重贫血和血小板减少定义为NIAID Division of Microbiology and Infectious Disease成人毒性表≥3级不良事件。
临床怎么用
- 对接受利奈唑胺治疗的广泛耐药结核患者,可监测神经病变症状和血红蛋白,若治疗4周血红蛋白下降>10%考虑将剂量从1200mg降至600mg。
局限性
- 结论基于模型模拟,需前瞻性测试确认获益风险比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated Nix-TB trial data (NCT02333799, N = 109) to provide dosing recommendations to potentially minimize linezolid toxicity in patients with extensively drug-resistant tuberculosis. . METHODS: A pharmacokinetic model and toxicodynamic models for peripheral neuropathy, hemoglobin, and platelets were developed. Simulations compared safety outcomes for daily linezolid of 1200 and 600 mg, with and without dose adjustments for toxicity. Severe neuropathy was based on symptom scores from the Brief Peripheral Neuropathy Screen. Severe anemia and thrombocytopenia were defined as ≥ grade 3 adverse events according to the NIAID Division of Microbiology and Infectious Disease Adult Toxicity table. RESULTS: Predicted concentration-time profiles were a major predictor in all toxicodynamic models. Simulations showed higher percentages of patients with severe neuropathy (median, 19%; 90% confidence interval [CI], 17%-22% vs 5%, 4%-7%) and severe anemia (15%, 12%-17% vs 1%, 0%-2%) between 1200 and 600 mg daily linezolid. No differences in severe thrombocytopenia were observed (median, <1% for both daily doses). Generally, neuropathy occurred after 3 to 6 months of treatment and, with protocol-specified management, reversed within 15 months after onset. Simulations indicated that a >10% decrease in hemoglobin level after 4 weeks of treatment would have maximum sensitivity (82%) and specificity (84%) for predicting severe anemia. Reducing the dose from 1200 to 600 mg triggered by this marker may prevent 60% (90% CI, 45%-72%) of severe anemia. CONCLUSIONS: Simple neuropathy symptom and hemoglobin monitoring may guide linezolid dosing to avoid toxicities, but prospective testing is needed to confirm the benefit-to-risk ratio.
引用
- Imperial MZ, Nedelman JR, Conradie F, et al. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022. PMID: 34604901. doi:10.1093/cid/ciab699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。